Characterization and management of adverse reactions (ARs) in patients with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (CLEAR study)

被引：0
|
作者：
Motzer, Robert [1 ]
George, Saby [2 ]
Merchan, Jaime R. [3 ]
Hutson, Thomas E. [4 ,5 ]
Song, Xun [6 ]
Perini, Rodolfo F. [6 ]
Xie, Ran [7 ]
Bapat, Urmi [7 ]
Ebaid, Basant [8 ]
Puente, Javier [9 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA
[2] Roswell Park Comprehens Canc Ctr, Dept Med, Buffalo, NY USA
[3] Univ Miami, Dept Med, Sylvester Comprehens Canc Ctr, Miami, FL USA
[4] Baylor Charles A Sammons Canc Ctr, Dept Med Oncol, Texas Oncol, Dallas, TX USA
[5] Texas A&M HSC Coll Med, Bryan, TX USA
[6] Merck & Co Inc, Rahway, NJ 07065 USA
[7] Eisai Inc, Nutley, NJ USA
[8] Eisai Australia Pty Ltd, Melbourne, Vic, Australia
[9] Hosp Clin Univ San Carlos, Dept Med Oncol, Madrid, Spain
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
196
引用
收藏
页码：121 / 122
页数：2
相关论文
共 50 条
  • [41] Pembrolizumab Plus Lenvatinib for Metastatic Renal Cell Carcinoma in a Patient on Hemodialysis
    Yamashita, Shimpei
    Kawabata, Hiroki
    Iwahashi, Yuya
    Muraoka, Satoshi
    Wakamiya, Takahito
    Kojima, Fumiyoshi
    Kohjimoto, Yasuo
    Murata, Shin-ichi
    Hara, Isao
    IJU CASE REPORTS, 2025,
  • [42] A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma
    Movva, Sujana
    Avutu, Viswatej
    Chi, Ping
    Dickson, Mark Andrew
    Gounder, Mrinal M.
    Kelly, Ciara Marie
    Keohan, Mary Louise
    Meyers, Paul A.
    Cohen, Seth M.
    Hensley, Martee Leigh
    Konner, Jason A.
    Schram, Alison M.
    Lefkowitz, Robert A.
    Erinjeri, Joseph Patrick
    Qin, Li-Xuan
    Salcito, Tiffany
    Seier, Kenneth
    Tap, William D.
    D'Angelo, Sandra P.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [43] A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma
    Movva, Sujana
    Avutu, Viswatej
    Chi, Ping
    Dickson, Mark Andrew
    Gounder, Mrinal M.
    Kelly, Ciara Marie
    Keohan, Mary Louise
    Nacev, Benjamin Alexander
    Rosenbaum, Evan
    Thornton, Katherine Anne
    Cohen, Seth M.
    Hensley, Martee Leigh
    Konner, Jason A.
    Schram, Alison M.
    Qin, Li-Xuan
    Lefkowitz, Robert A.
    Erinjeri, Joseph Patrick
    D'Angelo, Sandra P.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [44] LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma
    Choueiri, Toni K.
    Powles, Thomas
    Voss, Martin H.
    Plimack, Elizabeth R.
    Gurney, Howard
    Song, Yue
    Perini, Rodolfo F.
    Rodriguez-Lopez, Karla
    Rini, Brian, I
    FUTURE ONCOLOGY, 2023, 19 (40) : 2631 - 2640
  • [45] Combination lenvatinib plus pembrolizumab in the treatment of ovarian clear cell carcinoma: A case series
    Calo, Corinne A.
    Levine, Monica D.
    Brown, Morgan D.
    O'Malley, David M.
    Backes, Floor J.
    GYNECOLOGIC ONCOLOGY REPORTS, 2023, 46
  • [46] Final prespecified overall survival (OS) analysis of the phase 3 CLEAR trial: 4-year follow-up of lenvatinib plus pembrolizumab (L plus P) vs sunitinib (S) in patients with advanced renal cell carcinoma (aRCC)
    Motzer, Robert J.
    Porta, Camillo
    Eto, Masatoshi
    Powles, Thomas
    Grunwald, Viktor
    Hutson, Thomas E.
    Alekseev, Boris
    Rha, Sun Young
    Merchan, Jamie R.
    Goh, Jeffrey C.
    De Giorgi, Ugo
    Melichar, Bohuslav
    Hong, Sung-Hoo
    Gurney, Howard
    Rodriguez-Lopez, Karla
    He, Cixin S.
    Okpara, Chinyere E.
    McKenzie, Jodi
    Choueiri, Toni K.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2023, 19 : 72 - 73
  • [47] Genomic biomarkers of response to lenvatinib/pembrolizumab (Len/Pembro) in patients with advanced renal cell carcinoma
    Lee, Chung-Han
    DiNatale, Renzo G.
    Chowell, Diego
    Krishna, Chriag
    Makarov, Vladimir
    Shapnik, Natalie
    Murray, Samuel J.
    Carlo, Maria Isabel
    Voss, Martin H.
    Feldman, Darren R.
    Hakimi, A. Ari
    Adachi, Yusuke
    Minoshima, Yukinori
    Matsui, Junji
    Funahashi, Yasuhiro
    Perini, Rodolfo F.
    Nomoto, Kenichi
    Motzer, Robert J.
    Chan, Timothy An-thy
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [48] A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma
    Hutson, Thomas E.
    Michaelson, M. Dror
    Kuzel, Timothy M.
    Agarwal, Neeraj
    Molina, Ana M.
    Hsieh, James J.
    Vaishampayan, Ulka N.
    Xie, Ran
    Bapat, Urmi
    Ye, Weifei
    Jain, Rohit K.
    Fishman, Mayer N.
    EUROPEAN UROLOGY, 2021, 80 (02) : 162 - 170
  • [49] Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis
    Fleeman, Nigel
    Houten, Rachel
    Nevitt, Sarah
    Mahon, James
    Beale, Sophie
    Boland, Angela
    Greenhalgh, Janette
    Edwards, Katherine
    Maden, Michelle
    Bhattacharyya, Devarshi
    Chaplin, Marty
    McEntee, Joanne
    Chow, Shien
    Waddell, Tom
    HEALTH TECHNOLOGY ASSESSMENT, 2024, 28 (49)
  • [50] Axitinib in combination with pembrolizumab (AXI plus PEMBRO) in patients (pts) with advanced renal cell carcinoma (aRCC): Analysis of immune-related biomarkers
    Atkins, Michael
    Martini, Jean-Francois
    Plimack, Elizabeth
    McDermott, David
    Puzanov, Igor
    Fishman, Mayer
    Cho, Daniel
    Vaishampayan, Ulka
    Rosbrook, Brad
    Fernandez, Kathrine
    Tarazi, Jamal
    George, Saby
    Choueiri, Toni
    CANCER RESEARCH, 2019, 79 (13)
12345